← SynDRA
ZONISAMIDE
SynDRA canonical compound SYN0001686 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CA12 |
|---|
| Mechanism of action | T-type calcium channel blocker |
|---|
| Indication | epilepsy | seizures |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- SCN1A
- SCN2A
- SCN3A
- SCN11A
- CA12
- SCN4A
- CA1
- SCN5A
- SCN9A
- CA7
- SCN10A
- SCN7A
Mechanisms of action (all sources)
- Sodium channel blocker
- T-type calcium channel blocker
- SCN1A BLOCKER
- Sodium channel alpha subunit blocker
- SCN5A BLOCKER
- SCN4A BLOCKER
- SCN7A BLOCKER
- SCN2A BLOCKER
- SCN9A BLOCKER
- SCN3A BLOCKER
- SCN11A BLOCKER
- SCN8A BLOCKER
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADORA1
- NPY1R
- HRH2
- HRH3
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- LMNA
- MC3R
- MC4R
- MLNR
- MTARC1
- MTARC2
- NR1I2
- ADORA2A
- NR3C1
- OPRD1
- OPRK1
- OPRM1
- PDE3A
- PDE4D
- PGR
- PTGS2
- SAMHD1
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- SMN1
- HRH1
- HDAC6
- GMNN
- GHSR
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Carbonic Anhydrase Inhibitors
- Anticonvulsants
- Calcium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Cardiovascular Agents
- Central Nervous System Agents
- Membrane Transport Modulators
- Anti-epileptic Agent
- P-Glycoprotein Inhibitors
ATC classes
Cross-references
Synonyms
- ZONEGRAN
- ZONISADE
- Zonegran
- Zonisade
- exceglan
- excegram
- excegran
- zonegran
- Zonisamida
- Excegran
- AD-810
- CI-912
- N03AX15
- PD-110843
- Zonisamide mylan
- Exceglan
- Excegram
- Tremode
- Trerief
- Zonisamidum
- Elan brand of zonisamide
- Zonisamida [Spanish]
- Zonisamide monosodium
- Zonisamidum [Latin]
- SPR_2
- AD-810N
- E-2090
- Excegran (TN)
- Zonegran (TN)
- Zonegran, Zonisamide
- Zonisamide (ZNS)
- Zonisamide (JAN/USAN/INN)
- Zonisamide [USAN:BAN:INN:JAN]
- 1,2-Benzisoxazole-3-methanesulfonamide
- 1,2-benzoxazol-3-ylmethanesulfonamide
- 3-(Sulfamoylmethyl)-1,2-benzisoxazole
- 3-sulfamoylmethyl-1,2-benzisoxazole
Reported adverse events
- Vomiting
- Anxiety
- Ataxia
- Nausea
- Rash
- Constipation
- Agitation
- Tremor
- Nystagmus
- Diplopia
- Pruritus
- Irritability
Look up ZONISAMIDE in the interactive SynDRA portal →